Shanghai MicuRx Pharmaceutical Co., Ltd. (SHA:688373)
China · Delayed Price · Currency is CNY 4.490
-0.040 (-0.88%)
At close: Jun 11, 2026
SHA:688373 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -201.43 | -241.61 | -440.72 | -421.12 | -220.3 | -226.27 |
Depreciation & Amortization | 14.27 | 14.27 | 14.17 | 14.12 | 15.3 | 12.11 |
Other Amortization | 3.79 | 3.79 | 3.49 | 3.71 | 2.17 | 1.6 |
Loss (Gain) From Sale of Assets | -0 | -0 | -0.03 | -0 | -0.49 | 0.02 |
Loss (Gain) From Sale of Investments | -6.49 | -6.49 | -17.08 | -33.34 | -18.49 | -10.53 |
Stock-Based Compensation | 14.47 | 14.47 | 37.53 | 37.14 | 28.22 | 45.39 |
Provision & Write-off of Bad Debts | 0.25 | 0.25 | 0.77 | 0.33 | 0.2 | 0.03 |
Other Operating Activities | 8.52 | 12.67 | 12.88 | 9.18 | 7.06 | 5.13 |
Change in Accounts Receivable | -27.26 | -27.26 | -24.41 | 11.47 | -58.49 | -14.76 |
Change in Inventory | 2.68 | 2.68 | -15.42 | -15.63 | -10.88 | -5.58 |
Change in Accounts Payable | 17.06 | 17.06 | -18.87 | 66.92 | 28.71 | 11.28 |
Change in Unearned Revenue | - | - | - | -1.85 | -13 | 0.6 |
Operating Cash Flow | -174.14 | -210.18 | -447.18 | -329.08 | -240.01 | -180.98 |
Capital Expenditures | -0.55 | -0.55 | -0.91 | -7.66 | -12.18 | -22.91 |
Sale of Property, Plant & Equipment | 0 | 0 | 0.03 | - | 1.5 | - |
Investment in Securities | 145.05 | 159.26 | 495.51 | 305.24 | -737.6 | 35 |
Other Investing Activities | -0.51 | 6.78 | 20.17 | 37.05 | 14.86 | 10.11 |
Investing Cash Flow | 143.99 | 165.49 | 514.8 | 334.63 | -733.42 | 22.2 |
Long-Term Debt Issued | - | 205.7 | 105 | 60 | 148.75 | 53.25 |
Long-Term Debt Repaid | - | -131.63 | -32.34 | -75.01 | -84.35 | -19.33 |
Net Debt Issued (Repaid) | 4.78 | 74.07 | 72.66 | -15.01 | 64.4 | 33.92 |
Issuance of Common Stock | 3.11 | 3.11 | 1.98 | - | 981.77 | 5.09 |
Common Dividends Paid | -1.31 | - | -6.54 | -4.6 | -3.3 | -0.7 |
Other Financing Activities | -9.08 | -8.88 | - | - | -14.72 | -10.63 |
Financing Cash Flow | -2.5 | 68.31 | 68.09 | -19.61 | 1,028 | 27.68 |
Foreign Exchange Rate Adjustments | -2.27 | -2.02 | 0.14 | 0.45 | 1.16 | -0.2 |
Net Cash Flow | -34.92 | 21.6 | 135.86 | -13.61 | 55.88 | -131.3 |
Free Cash Flow | -174.69 | -210.73 | -448.1 | -336.74 | -252.18 | -203.89 |
Free Cash Flow Margin | -115.99% | -148.64% | -343.97% | -370.96% | -523.13% | -2661.81% |
Free Cash Flow Per Share | -0.26 | -0.32 | -0.68 | -0.51 | -0.43 | -0.39 |
Cash Interest Paid | 8.88 | 8.88 | - | - | - | - |
Cash Income Tax Paid | 12.33 | 12.22 | 27 | -9.87 | -7.2 | 0.39 |
Levered Free Cash Flow | -109.68 | -134.74 | -286.51 | -172.29 | -178.87 | -141.67 |
Unlevered Free Cash Flow | -100.93 | -126.69 | -279.54 | -165.95 | -173.36 | -138.4 |
Change in Working Capital | -7.52 | -7.52 | -58.2 | 60.9 | -53.67 | -8.47 |